Terms: = Lung cancer AND PSA AND Clinical Outcome
5 results:
1. Is
Gupta M; Karthikeyan G; Choudhury PS; Sharma A; Singh A; Rawal S
Hell J Nucl Med; 2020; 23(3):312-320. PubMed ID: 33367303
[TBL] [Abstract] [Full Text] [Related]
2. Development of psoriatic arthritis during nivolumab therapy for metastatic non-small cell lung cancer, clinical outcome analysis and review of the literature.
Ruiz-Bañobre J; Pérez-Pampín E; García-González J; Gómez-Caamaño A; Barón-Duarte FJ; López-López R; Vázquez-Rivera F
Lung Cancer; 2017 Jun; 108():217-221. PubMed ID: 28625638
[TBL] [Abstract] [Full Text] [Related]
3. Abiraterone acetate in metastatic castration-resistant prostate cancer - the unanticipated real-world clinical experience.
Poon DM; Chan K; Lee SH; Chan TW; Sze H; Lee EK; Lam D; Chan MF
BMC Urol; 2016 Mar; 16():12. PubMed ID: 27001043
[TBL] [Abstract] [Full Text] [Related]
4. EphA6 promotes angiogenesis and prostate cancer metastasis and is associated with human prostate cancer progression.
Li S; Ma Y; Xie C; Wu Z; Kang Z; Fang Z; Su B; Guan M
Oncotarget; 2015 Sep; 6(26):22587-97. PubMed ID: 26041887
[TBL] [Abstract] [Full Text] [Related]
5. PTEN deletion and heme oxygenase-1 overexpression cooperate in prostate cancer progression and are associated with adverse clinical outcome.
Li Y; Su J; DingZhang X; Zhang J; Yoshimoto M; Liu S; Bijian K; Gupta A; Squire JA; Alaoui Jamali MA; Bismar TA
J Pathol; 2011 May; 224(1):90-100. PubMed ID: 21381033
[TBL] [Abstract] [Full Text] [Related]
